Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OV5398PDX RNAseq]

ABSTRACT: We performed RNA sequencing on tumors harvested from OV5398 (ovarian) PDX treated for 40-50 days with either control vehicle (PEG), 100 mg/kg BID INX-315 or 200 mg/kg QD INX315.

ORGANISM(S): Homo sapiens

PROVIDER: GSE243151 | GEO | 2023/11/22

REPOSITORIES: GEO